- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc stock price live, this page displays NASDAQ BBIO stock exchange data. View the BBIO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the BridgeBio Pharma Inc real time stock price chart below.
What Is the BridgeBio Pharma Inc Stock Price Today?
The BridgeBio Pharma Inc stock price today is 72.29.
What Is the Stock Symbol for BridgeBio Pharma Inc?
The stock symbol for BridgeBio Pharma Inc is "BBIO."
What Stock Exchange Does BridgeBio Pharma Inc Trade On?
BridgeBio Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is BridgeBio Pharma Inc a Good Stock to Buy?
Determining whether BridgeBio Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BBIO quote. (ISIN: US10806X1028)
What Is the BridgeBio Pharma Inc Stock Price Today?
The BridgeBio Pharma Inc stock price today is 72.29.
What Is the Stock Symbol for BridgeBio Pharma Inc?
The stock symbol for BridgeBio Pharma Inc is "BBIO."
What Stock Exchange Does BridgeBio Pharma Inc Trade On?
BridgeBio Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is BridgeBio Pharma Inc a Good Stock to Buy?
Determining whether BridgeBio Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BBIO quote. (ISIN: US10806X1028)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
67.82
72.98
52 wk Range
28.33
81.33
Earnings results expected in 9 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
67.8272.98
52 wk Range
28.3381.33
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BBIO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
93.30
Upside
+29.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
BridgeBio Pharma Inc Company Profile
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
BridgeBio Pharma Inc SWOT Analysis
Attruby's Success | BridgeBio's flagship drug Attruby exceeds sales expectations, driving market optimism. Strong patient adoption and strategic commercialization fuel growth prospects. |
Pipeline Potential | Explore BridgeBio's robust late-stage pipeline, including promising candidates like Encaleret and Infigratinib, with blockbuster potential in genetic disease treatments. |
Financial Outlook | Delve into BridgeBio's financial position, with analysts projecting continued investment in R&D. Price targets range from $41 to $95, suggesting significant upside potential. |
Market Dynamics | Learn about BridgeBio's competitive advantages in the ATTR-CM market and potential challenges, including increasing competition and regulatory risks in drug development. |
BridgeBio Pharma Inc Earnings Call Summary for Q2/2025
- Q2 2025 revenue surged to $110.6M, up from $2.2M YoY, beating forecasts by 10.87%; EPS missed at -$0.95 vs -$0.75 expected
- Stock rose 3.06% after-hours to $47.75; company maintains $756.9M cash position with 95.35% gross profit margin
- Atruvi product launch shows strong growth; three potential $1B+ market launches planned for 2026-2027
- CEO highlights transformation to integrated biopharma; analysts maintain strong buy consensus despite high valuation
- Risks include high operating expenses, market competition, and potential regulatory hurdles for upcoming product launches
Last Updated: 08/06/2025, 06:16 AM
Read Full TranscriptCompare BBIO to Peers and Sector
Metrics to compare | BBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBBIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.5x | −1.4x | −0.5x | |
PEG Ratio | 0.23 | −0.01 | 0.00 | |
Price/Book | −7.2x | 1.5x | 2.6x | |
Price / LTM Sales | 39.4x | 204.8x | 3.3x | |
Upside (Analyst Target) | 26.0% | 97.9% | 45.0% | |
Fair Value Upside | Unlock | 11.5% | 5.1% | Unlock |
Analyst Ratings
20 Buy
1 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 93.30
(+29.06% Upside)
Earnings
Latest Release
Oct 29, 2025
EPS / Forecast
-0.95 / -0.88
Revenue / Forecast
120.70M / 107.62M
People Also Watch
FAQ
What Is the BridgeBio Pharma (BBIO) Stock Price Today?
The BridgeBio Pharma stock price today is 72.29
What Stock Exchange Does BridgeBio Pharma Trade On?
BridgeBio Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for BridgeBio Pharma?
The stock symbol for BridgeBio Pharma is "BBIO."
What Is the BridgeBio Pharma Market Cap?
As of today, BridgeBio Pharma market cap is 13.93B.
What Is BridgeBio Pharma's Earnings Per Share (TTM)?
The BridgeBio Pharma EPS (TTM) is -4.18.
When Is the Next BridgeBio Pharma Earnings Date?
BridgeBio Pharma will release its next earnings report on Feb 18, 2026.
From a Technical Analysis Perspective, Is BBIO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has BridgeBio Pharma Stock Split?
BridgeBio Pharma has split 0 times.
How Many Employees Does BridgeBio Pharma Have?
BridgeBio Pharma has 728 employees.
What is the current trading status of BridgeBio Pharma (BBIO)?
As of Feb 09, 2026, BridgeBio Pharma (BBIO) is trading at a price of 72.29, with a previous close of 68.05. The stock has fluctuated within a day range of 67.82 to 72.98, while its 52-week range spans from 28.33 to 81.33.
What Is BridgeBio Pharma (BBIO) Price Target According to Analysts?
The average 12-month price target for BridgeBio Pharma is USD93.30, with a high estimate of USD157 and a low estimate of USD65. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +29.06% Upside potential.
What Is the BBIO Premarket Price?
BBIO's last pre-market stock price is 69.64. The pre-market share volume is 510.00, and the stock has decreased by 1.59, or 2.34%.
What Is the BBIO After Hours Price?
BBIO's last after hours stock price is 73.00, the stock has decreased by 0.71, or 0.98%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.